How Novartis Is Making SENSE Of Clinical Data In Digital Age

06 Feb 2019

The Swiss major has been showcasing its Nerve Live data analytics platform, where staff stationed at its SENSE operations center in Basel can monitor 500 or so clinical studies to predict - and stop - potential delays.

The buzz has been deafening for years across the pharmaceutical sector about how the digital revolution is going to transform the way business is done but Novartis AG has been demonstrating a system that is already up and running and allows it to make sense of big data and manage hundreds of clinical trials worldwide from a 'control tower' in Switzerland.

CEO Vas Narasimhan repeatedly states that his vision is to create the leading medicines company in the world, powered by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Santen Sees Potential In Myopia Market After Ryjunea Approval

06 Jun 2025

• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

06 Jun 2025

• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

06 Jun 2025

• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

06 Jun 2025

• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

05 Jun 2025

• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.